Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections.

Read more at globenewswire.com